Statins and cancer risk: What do we know and where do we go from here?

Epidemiology

Volumn 18, Issue 2, 2007, Pages 194-196

  Moorman, Patricia G ^a   Hamilton, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION;

CHEMOPREVENTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK; RISK REDUCTION BEHAVIOR;

EID: 33847036323     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000254699.31405.e2     Document Type: Review

References (27)

1. Anonymous. Top 200 Drugs of 2005. Pharmacy Times May 2006; http://www.pharmacytimes.com. Accessed December 7, 2006.
2. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294:1773-1781.
3. Baigent C, Keech A, Kearney PM, et al, for the Cholesterol Treatment Trialists (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
4. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
5. Collins R, Armitage J, Parish S, et al, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
6. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
7. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J. 2003;24:225-248.
8. LaRosa JC. Pleitropic effects of statins and their clinical significance. Am J Cardiol. 2001;88:291-293.
9. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10-19.
10. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
11. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24:4808-4817.
12. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716 -723.
13. Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a meta-analysis of seven randomized trials and nine observational studies. J Clin Oncol. 2005;23:8606-8612.
14. Dellavalle RP, Drake A, Graber M, et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev. 2005;4:CD003697.
15. Friis S, Olsen J. Statin use and cancer risk: an epidemiologic review. Cancer Invest. 2006;24:413-424.
16. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363-2368.
17. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388-2394.
18. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643-647.
19. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-2192.
20. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98:69-72.
21. Cauley JA, McTiernan A, Rodabaugh RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006;98:700-707.
22. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of ten cancers. Epidemiology. 2006;in press.
23. Drug Facts and Comparisons. 58th ed. St. Louis, MO: Wolters Kluwer Health; 2003;652-656.
24. Kumar AS, Benz CC, Esserman LJ. Clinical trials are required to prove the chemopreventive worth of statins. Arch Intern Med. 2006;166:1143.
25. Sprague J, Wood M. Breast cancer prevention: time for randomized controlled trials with statins. Arch Intern Med. 2006;166:1143-1144.
26. Sherwin RW, Wentworth DN, Cutler JA, et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:943-948.
27. Knekt P, Reunanen A, Aromaa A, et al. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol. 1988;41:519-530.